From SNPedia
rs2108622 is a SNP in the cytochrome P450, family 4, subfamily F, polypeptide 2
CYP4F2 gene.
[PMID 18787519] In the males rs2108622(G) was significantly higher in cerebral infarction patients (P = 0.025)
[PMID 19207028] A study of Italian patients concluded that rs2108622(T;T) patients require 5.49 mg/day of warfarin versus 2.93 mg/day for (C;C) patients. Analysis of variance indicates that about 7% of mean weekly warfarin dose variance is explained by CYP4F2 genotype.
| ? | (C;C) (C;T) (T;T) |
|---|
 |
[PMID 19300499] A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose.
[PMID 19097922] A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.
Related to CYTOCHROME P450, FAMILY 4, SUBFAMILY F, POLYPEPTIDE 2; CYP4F2
according to
omim 604426. See
also[PMID 19741565] Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy
| PharmGKB | PA161149199 |
| Name | CYP4F2:V433M |
| Annotation | This variant is found to have clinical impact on stable warfarin dose. Patients with 2 TT alleles were reported to require approximately 1 mg/day more warfarin than patients with 2 CC alleles. This variant affects enzyme acitivity and was shown to decrease 20-HETE production in a reconstituted recombinant protein system to approximately 60% of the wild-type enzyme. |
| Gene | CYP4F2 |
| Featue | Exon/NonSyn |
| Evidence | PubMed ID:17341693; PubMed ID:18250228 |
| Drugs | warfarin |
| Diseases | |
| Curation Level | Curated |
[PMID 20182420] A study of 370 Brazilian ("admixed") patients concludes that prospective CYP4F2 genotyping is of little value to these patients, presumably due to ethnic-based differences.
